Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Phase II Randomized, Double-blind, Placebo-controlled Study of LEE011(Ribociclib) or Placebo in Combination With Endocrine Therapy for the Treatment of Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer, Including a Subset With Pharmacokinetic Analysis.

ClinicalTrials.gov Identifier: NCT03671330

Novartis Reference Number: CLEE011A2206

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This is a Phase II randomized, double-blind, placebo-controlled study involving premenopausal and postmenopausal Chinese women plus an open-label single arm of pharmacokinetic cohort of LEE011 in combination with Letrozole in Chinese postmenopausal women with HR+, HER2- negative advanced breast cancer.

Three cohorts of patients will be enrolled: PK cohort, premenopausal cohort, and postmenopausal cohort.

Condition 
Breast Cancer
Phase 
Phase 2
Overall status 
Active, not recruiting
Enrollment count 
327 participants
Start date 
Aug 29, 2018
Completion date 
Dec 12, 2023
Gender 
Female
Age(s)
18 Years - 60 Years (Adult)

Interventions

Drug
Ribociclib Placebo
Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
Drug
Ribociclib
Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
Drug
NSAI: Letrozole or Anastrazole
Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption). Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history. For postmenopausal and PK cohorts, all patients will be on Letrozole.
Drug
Letrozole
Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
Drug
Goserelin
Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle

Eligibility Criteria

Inclusion Criteria:

Patient has a histologically and/or cytologically confirmed diagnosis of estrogen receptor (ER) positive and/or progesterone receptor positive breast cancer by local laboratory (based on most recently analyzed biopsy).
Patient has HER2-negative breast cancer (based on most recently analyzed biopsy) defined as a negative in situ hybridization test or an Immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing.

Patient must have either:

Measurable disease, i.e., at least 1 measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (a lesion at a previously irradiated site may only be counted as a target lesion if there is a clear sign of progression since the irradiation). OR
If no measurable disease is present, then at least 1 predominantly lytic bone lesion must be present (patients with no measurable disease and only 1 predominantly lytic bone lesion that has been previously irradiated are eligible if there is documented evidence of disease progression of the bone lesion after irradiation).
Patient has ECOG performance status 0 or 1.

For premenopausal cohort:

Patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent and has signed informed consent before any trial related activities are conducted and according to local guidelines.
Confirmed negative serum pregnancy test before starting study treatment or patient has had a hysterectomy.
Patient has advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer not amenable to curative therapy (e.g.

surgery and/or radiotherapy).

Patients who received ≤ 14 days of a NSAI (letrozole or anastrozole) with or without goserelin or goserelin ≤ 28 days for advanced breast cancer prior to randomization are eligible. Patients must continue treatment with the same hormonal agent + goserelin during the study. No treatment interruption is required for these patients prior to randomization.
Patients who have received up to 1 line of chemotherapy for advanced breast cancer and have been discontinued 28 days before randomization are eligible.

For postmenopausal cohort:

Patient is an adult, female ≥ 18 years old at the time of informed consent and has signed informed consent before any trial related activities and according to local guidelines.
Women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.

Exclusion Criteria:

Patient who has received a prior CDK4/6 inhibitor.
Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment
Patient with CNS metastases.
Patient who has not had resolution of clinical and laboratory acute toxicities related to prior anti-cancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Grade ≤1.
Patient has a known history of Human immunodeficiency Virus (HIV) infection (testing not mandatory).
Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
Patient is currently receiving any of the substances as defined in the protocol that cannot be discontinued 7 days prior to the start of the treatment:

For premenopausal cohort:

Pregnant or nursing (lactating) women.
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study treatment and for 21 days after stopping study medication.

Note: Use of oral (estrogen and progesterone), transdermal, injected or implanted hormonal methods of contraception as well as hormonal replacement therapy is not allowed in this study.

For postmenopausal cohort:

- Patient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer.

Note: Patients who received neo (adjuvant) therapy for breast cancer are eligible. If the prior neo (adjuvant) therapy included letrozole or anastrozole, the disease free interval must be greater than 12 months from the completion of treatment until randomization.

- Patients who received ≤ 14 days of letrozole or anastrozole for advanced disease prior to randomization are eligible.

Other protocol-defined inclusion/exclusion may apply.

Study Locations

China
Novartis Investigative Site
-
Hefei, 230001
Anhui
China
Novartis Investigative Site
-
Chongqing, 404100
Chongqing
China
Novartis Investigative Site
-
Guangzhou, 510000
Guangdong
China
Novartis Investigative Site
-
Shijiazhuang, 050011
Hebei
China
Novartis Investigative Site
-
Harbin, 150081
Heilongjiang
China
Novartis Investigative Site
-
Changsha, 410013
Hunan
China
Novartis Investigative Site
-
Nanjing, 210029
Jiangsu
China
Novartis Investigative Site
-
Suzhou, 215004
Jiangsu
China
Novartis Investigative Site
-
Nanchang, 330009
Jiangxi
China
Novartis Investigative Site
-
Chang Chun, 130021
Jilin
China
Novartis Investigative Site
-
Shengyang, 110016
Liaoning
China
Novartis Investigative Site
-
Shengyang, 110042
Liaoning
China
Novartis Investigative Site
-
Xian, 710061
Shanxi
China
Novartis Investigative Site
-
Chengdu, 610041
Sichuan
China
Novartis Investigative Site
-
Tianjin, 300060
Tianjin
China
Novartis Investigative Site
-
Kunming, 650106
Yunnan
China
Novartis Investigative Site
-
Hangzhou, 310006
Zhejiang
China
Novartis Investigative Site
-
Hangzhou, 310016
Zhejiang
China
Novartis Investigative Site
-
Beijing, 100036
-
China
Novartis Investigative Site
-
Beijing, 100044
-
China
Novartis Investigative Site
-
Fuzhou, 350001
-
China
Novartis Investigative Site
-
Qingdao, 266000
-
China
Novartis Investigative Site
-
Shanghai, 200025
-
China
Novartis Investigative Site
-
Shanghai, 200032
-
China

Have a question?

Call 1-999-669-6682 or email [email protected]